HNRNPK and acute promyelocytic leukemia: This study is the first to demonstrate both the hnRNP K and SET profiles in the same APL patients and in cell lines simultaneously, as well as their involvement in ATRA‐induced differentiation of leukemic promyelocytes and to propose an ERK inhibitor combined with ATO as a potential new therapy for APL patients.